Skip to main content

MBI Distributing, Inc. [Molecular Biologics] Over-The-Counter Eye Drops and Pain-Relieving Drugs

November 30, 2005

Audience: Consumers, caregivers and healthcare professionals

[Posted 11/30/2005] FDA notified consumers, caregivers, and healthcare professionals that MBI Distributing, Inc. (MBI), also known as Molecular Biologics, an over-the-counter [OTC] drug manufacturer of eye drops and other products will cease manufacturing and distributing drugs until it corrects manufacturing deficiencies and other violations. MBI's product line includes eye drops sold under the brand names Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C, as well as several OTC pain relieving drugs. These products are sold by retailers nationwide.

FDA determined that the firm lacked manufacturing controls to ensure that its eye drops were sterile. FDA has also determined that two of the firm's eye drop brands, Visitein and Clarity Vision for Life, are unapproved drugs. In addition, three of the firm's OTC pain relieving drugs, Biogesic, Bio-Ice, and Bio-Heat, do not provide adequate warnings for their safe use. FDA recommends that consumers, health care providers, and caregivers dispose of the Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C brands of eye drops and the Biogesic, Bio-Ice, and Bio-Heat pain relieving drugs.

[November 29, 2005 - News Release - FDA]

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.